Amicus Therapeutics (NASDAQ:FOLD) to Release Q3 2008 Earnings November 3

Amicus Therapeutics (NASDAQ:FOLD) will release the third quarter earnings for 2008 on Monday, November 4 after the close of the stock markets.  The financial results will be discussed in a conference call at 5:00 pm ET that afternoon.  Intersted parties may hear the call by dialing 877-419-6591 or 719-325-4858 for international callers. 

Amicus Therapeutics, Inc. (Amicus) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein, increasing the stability of the protein and helping it fold into the correct three-dimensional shape.

The Company’s lead products in development are Amigal for Fabry disease, Plicera for Gaucher disease and AT2220 for Pompe disease. The standard of treatment for Fabry, Gaucher and Pompe is enzyme replacement therapy. In November 2007, the Company entered into a collaboration with Shire Pharmaceuticals Ireland Ltd. (Shire), to jointly develop its three lead pharmacological chaperone compounds for lysosomal storage disorders.

Read more Business News on The Global Market Directory.

About The Global Market Directory (TheGMD)

TheGMD is a financial networking community for Public Companies, Brokerage Firms, Stock Brokers and Individuals. Members can network and link with each other, participate in discussions on financial stock message boards, display pictures and upload videos.

The GMD is a member of the TransWorldNews, Inc. family of sites. Members can distribute press releases through The GMD and receive distribution over all TransWorldNews news outlets.

Create your profile on The Global Market Directory